Our mission is to develop novel Id-protein targeted small molecule therapeutics in oncology and vascular diseases of the eye the eye.
Background and History of the Company
We are a public bio-pharmaceutical company dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration.
AngioGenex was created to capture the full potential of the Id platform. It currently owns unencumbered exclusive world-wide rights under issued and pending patents to a novel class of drugs that target the ID proteins. Central to this strategy is the company’s symbiotic relationship with MSKCC, which includes a coordinated R&D program and clinical trial plan. MSKCC holds common stock in the Company that was granted in return for the efforts it contributed to Dr. Benezra’s early efforts in discovering the role of the ID proteins and their potential as targets for disease intervention.
AngioGenex is a publicly traded company, trading on the OTC exchange with the ticker symbol AGGX. Our filings with the Securities and Exchange Commission(SEC) can be found here.
Our office is located at:
425 Madison Avenue, Suite 902
New York, NY, 10017
For immediate questions regarding our technology, reach Dr. Robert Benezra at or 646-888-2112
For immediate administrative and financial questions, reach Mr. Michael Strage at or 347-468-6799
For all other queries, reach us at 212-874-6608 or via email at
Jeffrey J. King, Esq.
PATENT NETWORKS LAW GROUP PLLC
5000 Carillon Point - Suite 400
Kirkland, WA 98033
Telephone: (425) 576-4235
Facsimile: (425) 576-4236
Direct Dial: (425) 281-6574
Davis Polk & Wardwell LLP
450 Lexington Avenue | New York, NY 10017
+1 212 450 4762 tel | +1 212 701 5762 fax